Advertisement


Bernard J. Escudier, MD, on RCC: Results From the IMmotion151 Trial

2018 ASCO Annual Meeting

Advertisement

Bernard J. Escudier, MD, of Gustave Roussy, discusses patient-reported outcomes for atezolizumab plus bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma (Abstract 4511).



Related Videos

Lymphoma
Immunotherapy

Laurie Helen Sehn, MD, MPH, on FL and DLBCL: Results From a Treatment Trial

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses phase II study findings on polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (Abstract 7507).

Breast Cancer

Rebecca A. Dent, MD, on Triple-Negative Breast Cancer: Results From the LOTUS Trial

Rebecca A. Dent, MD, of the National Cancer Centre Singapore, discusses phase II study findings on first-line ipatasertib plus paclitaxel for locally advanced/metastatic triple-negative breast cancer (Abstract 1008).

Prostate Cancer

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, on Prostate Cancer: Results of the SPCG-13 Trial

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, MD, PhD, of Tampere University Hospital, discusses phase III findings on adjuvant docetaxel and surveillance after radical radiotherapy for intermediate- and high-risk prostate cancer (Abstract 5000).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Elizabeth R. Plimack, MD, on RCC: Perspectives on KEYNOTE-427 and IMmotion151

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, offer their analysis of two key studies presented in renal cell cancer.

Breast Cancer

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Results From the PAKT Trial

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (Abstract 1007).

Advertisement

Advertisement




Advertisement